查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1291413

抗肥胖症药物市场：2023-2028年全球行业趋势、份额、规模、增长、机会和预测

Anti-Obesity Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

市场概况：

全球抗肥胖药物市场规模在2022年达到20亿美元。展望未来，IMARC集团预计到2028年，市场规模将达到40亿美元，在2023-2028年期间表现出11.7%的增长率（CAGR）。

抗肥胖药物的目的是减少或控制体重，一般只在病态肥胖的情况下进行医疗处方。它们有助于减少渴望和控制强迫性饮食，特别是对甜食和高脂肪、高盐和高热量食品的渴望。它们还能提供独立的健康益处，如控制血压、有害脂质水平、腰围、糖分水平和非酒精性脂肪肝（NAFLD），并将主要心血管疾病（CVDs）和糖尿病肾病进展的风险降至最低。

抗肥胖症药物的市场趋势：

抗肥胖症药物的最新进展使个人有可能获得临床上显著的体重减轻。这与久坐不动的生活方式导致的肥胖症的广泛流行相融合，是创造市场积极前景的关键因素之一。此外，肥胖增加了患2型糖尿病（T2D）、心血管疾病（CVD）以及食道、结肠和直肠、肝脏、胆囊、胰腺和肾脏癌症的风险。它还会导致许多心理、神经、肺、胃肠、肾、肌肉骨骼和内分泌疾病。除此之外，睡眠不足、昼夜不同步、长期压力以及抗癫痫和精神药物使用的增加，可能进一步诱发体重增加。再加上越来越多的有助于调节食欲和食物渴望的抗肥胖药物（AOMs）获得批准，正在推动市场的增长。除此以外，减肥有助于改善个人的生活质量、活动能力、日常功能和心理健康。这一点，再加上健康意识的增强，制药业的蓬勃发展，以及对与体重过重密切相关的疾病管理的日益重视，预计将刺激市场的增长。

本报告回答的关键问题：

  • 2022年全球抗肥胖药物市场的规模是多少？
  • 2023-2028年，全球抗肥胖药物市场的预期增长率是多少？
  • 推动全球抗肥胖药物市场的关键因素是什么？
  • COVID-19对全球抗肥胖药物市场的影响是什么？
  • 全球抗肥胖药物市场基于药物类别的细分情况是什么？
  • 基于药物类型的全球抗肥胖药物市场的细分情况如何？
  • 基于分销渠道的全球抗肥胖药物市场的细分情况如何？
  • 全球抗肥胖药物市场的主要地区有哪些？
  • 谁是全球抗肥胖药物市场的主要参与者/公司？

目录

第一章：前言

第二章：范围和方法

  • 研究的目标
  • 利益相关者
  • 数据来源
    • 主要来源
    • 二级来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球抗肥胖症药物市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：按药物类别分類的市场

  • 周边作用药物
    • 市场趋势
    • 市场预测
  • 中枢作用药物
    • 市场趋势
    • 市场预测

第7章 ：按药物类型分類的市场

  • 处方药
    • 市场趋势
    • 市场预测
  • 非处方药
    • 市场趋势
    • 市场预测

第8章：按分销渠道分類的市场

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药店
    • 市场趋势
    • 市场预测
  • 网上药店
    • 市场趋势
    • 市场预测

第九章：按地区分類的市场

  • 北美洲
    • 美国
      • 市场趋势
      • 市场预测
    • 加拿大
      • 市场趋势
      • 市场预测
  • 亚太地区
    • 中国
      • 市场趋势
      • 市场预测
    • 日本
      • 市场趋势
      • 市场预测
    • 印度
      • 市场趋势
      • 市场预测
    • 韩国
      • 市场趋势
      • 市场预测
    • 澳大利亚
      • 市场趋势
      • 市场预测
    • 印尼
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 欧洲
    • 德国
      • 市场趋势
      • 市场预测
    • 法国
      • 市场趋势
      • 市场预测
    • 英国
      • 市场趋势
      • 市场预测
    • 意大利
      • 市场趋势
      • 市场预测
    • 西班牙
      • 市场趋势
      • 市场预测
    • 俄罗斯
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场趋势
      • 市场预测
    • 墨西哥
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 中东和非洲
    • 市场趋势
    • 按国家分類的市场
    • 市场预测

第十章：SWOT分析

  • 概述
  • 优势
  • 劣势
  • 机会
  • 威胁

第十一章 ：价值链分析

第十二章 ：波特斯五力分析

  • 概述
  • 买方的讨价还价能力
  • 供应商的讨价还价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章 ：价格分析

第十四章：竞争格局

  • 市场结构
  • 主要参与者
  • 主要参与者的概况
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Gelesis
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Norgine B.V.
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals Inc.
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
Product Code: SR112023A5544

Market Overview:

The global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2028, exhibiting a growth rate (CAGR) of 11.7% during 2023-2028.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, drug type and distribution channel.

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

  • Prescription Drugs
  • OTC Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report:

  • What was the size of the global anti-obesity drugs market in 2022?
  • What is the expected growth rate of the global anti-obesity drugs market during 2023-2028?
  • What are the key factors driving the global anti-obesity drugs market?
  • What has been the impact of COVID-19 on the global anti-obesity drugs market?
  • What is the breakup of the global anti-obesity drugs market based on the drug class?
  • What is the breakup of the global anti-obesity drugs market based on the drug type?
  • What is the breakup of the global anti-obesity drugs market based on distribution channel?
  • What are the key regions in the global anti-obesity drugs market?
  • Who are the key players/companies in the global anti-obesity drugs market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Anti-Obesity Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Class

  • 6.1  Peripherally Acting Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Centrally Acting Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7   Market Breakup by Drug Type

  • 7.1  Prescription Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  OTC Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8   Market Breakup by Distribution Channel

  • 8.1  Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10  SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Boehringer Ingelheim International GmbH
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2  Currax Pharmaceuticals LLC
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3  Gelesis
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4  GlaxoSmithKline plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5  Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6  Norgine B.V.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7  Novo Nordisk A/S 
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8  Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9  Rhythm Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10  SHIONOGI & Co. Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11  Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12  Vivus LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2022
  • Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
  • Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
  • Table 7: Global: Anti-Obesity Drugs Market: Key Players